Efficacy and Safety of Botulinum Toxin Type A for Moderat... | NCT01940991

Studies
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991

Sponsor

Revance Therapeutics, Inc.

Status

Completed

Last Update Posted

Jan 31, 2014Estimated

Enrollment

82Actual

Phase

Phase 2

Conditions

Skin Aging

Interventions

Placebo
Botulinum Toxin Type A

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Dec 2013

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Aug 2013

Primary Completion Date

Nov 2013Actual

Completion Date

Nov 2013Actual

First Submitted Date

Sep 9, 2013

First Submission Date that Met QC Criteria

Sep 9, 2013

First Posted Date

Sep 12, 2013Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Dec 27, 2013

Certification/Extension First Submitted that Passed QC Review

Dec 27, 2013

Certification/Extension First Posted Date

Jan 31, 2014Estimated

Last Update Submitted Date

Dec 27, 2013

Last Update Posted Date

Jan 31, 2014Estimated

Description Module

Brief Summary

This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 2

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

82Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Dose B	Placebo Comparator	Dose B: Placebo	Drug: Placebo
Dose A	Experimental	Dose A: Botulinum Toxin Type A	Drug: Botulinum Toxin Type A

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Placebo	Drug	Placebo, Dose B; dose applied to the lateral canthal lines	Dose B

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Composite endpoint	Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines	Week 4

Secondary Outcomes

Measure	Description	Time Frame
Investigator Global Assessment with 2 points or greater improvement from baseline	Proportion of subjects with 2 point or greater improvement from baseline using the Investigator Global Assessment	Week 4
Investigator Global Assessment with 1 point or greater improvement from baseline

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Moderate to severe crow's feet lines
Female or male, 18 to 65 years of age and in good general health
Women of childbearing potential (WOCBP) must agree to use an effective method of birth control during the course of the study

Exclusion Criteria:

Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A
Muscle weakness or paralysis, particularly in the area receiving study treatment
Active skin disease or irritation at the treatment area
Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart
Treatment with Botulinum Toxin Type A for crow's feet lines in the last 6 months or 3 months anywhere in the body

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

65 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Dermatology Research Institute		Coral Gables	Florida	33146	United States

Intervention Browse Module

MeSH Terms

ID	Term
D019274	Botulinum Toxins, Type A

Ancestor Terms

ID	Term
D001905	Botulinum Toxins
D008666	Metalloendopeptidases
D010450	Endopeptidases
D010447	Peptide Hydrolases

Browse Leaves

Not provided

Browse Branches

Not provided